Amarin Corp Plc (AMRN)

[CaptBeer]

I recently came across this interesting International Patent issued to Amarin on 10/06/22 for the combination therapy of EPA + Colchicine (WO2022212655A1) to reduce the risk of cardiovascular events in subjects on statin therapy.

https://worldwide.espacenet.com/patent/search/family/083459738/publication/WO2022212655A1?q=ICOSAPENT%2C%20AMARIN

Colchicine is an ancient drug used since about 1500 BC for anti-inflammatory conditions. In 1961 the FDA approved colchicine to relieve symptoms associated with gout.

More recently, the Colchicine Cardiovascular Outcomes Trial (COLCOT NCT02551094) demonstrated a 25-30% reduction in CVE’s in ASCVD patients. The drug works by targeting Residual Inflammatory Risk.

In the future, combination therapy with lipid-lowering and anti-inflammatory medications” (like VASCEPA®/VAZKEPA®, my words), “may be used more frequently for patients with ASCVD.”

https://www.sciencedirect.com/science/article/abs/pii/S0735109723059600?via%3Dihub